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identified at IMSS and 631 at ISSSTE, 2,570 and 536 of them with NSCLC. A 4.2% ALK+ 
rate was assumed. Direct medical costs of standard treatment for LC were obtained 
from a published source. Cost for crizotinib was given by the manufacturer. All costs 
are expressed in 2014 USD ($1USD= $13MXN). Two scenarios are presented: 1) world 
without crizotinib, where all patients with LC are treated with standard treatment; 2) 
world with crizotinib, where patients with ALK+ advanced NSCLC are treated with 
crizotinib and all other LC patients are treated with standard treatment. Results: 81 
and 17 ALK+ advanced NSCLC patients were identified in IMSS and ISSTE, respectively. 
Total costs in a world “without” and “with” crizotinib using a one-year time horizon is 
$50.3 and $52.9 million, respectively, for IMSS. For ISSSTE, total costs were $10.5 versus 
$11.1 million. The combined incremental budget impact across both public health care 
institutions is 5.2%. ConClusions: Crizotinib, the only drug approved for the treat-
ment of ALK+ advanced NSCLC patients has a minimal incremental budget impact on 
the overall expenditure within the two main Mexican public health care institutions.
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objeCtives: To estimate the budget impact of everolimus-exemestane versus the 
most commonly used regimens in the Egyptian practice; gemcitabine-paclitaxel 
and capecitabine-docetaxel for a health care plan that introduces everolimus 
for post-menopausal hormone receptor positive, human epidermal growth fac-
tor receptor-2 negative metastatic breast cancer (HR+, HER2-MBC) patients over 
three years. Methods: Drug and medical budget impacts (2013 EGP) were esti-
mated over the first three years of the three drug regimens use from the health 
insurance perspective. Epidemiology data were used to estimate target popula-
tion size. The treatment data for MBC patients were obtained from published and 
nonpublished sources. The model considered 2 scenarios—without (pre) and with 
(post) everolimus-exemestane. Monthly medical costs were calculated for 
the pre- and post-progression phase. Results were considered on a per member 
per month (PMPM) basis to examine the relative impact on the plan. Deterministic 
sensitivity analyses were conducted. Results: In a real-world 6,055,902 targeted 
patients, 288,261 of them were found to be candidates for everolimus-exemestane 
regimen. For patients taking gemcitabine-paclitaxel and capecitabine-docetaxel 
regimens, the estimated incremental cost PMPM was LE3.00 and LE2.94 respec-
tively for each after three years. The estimated incremental cost PMPM for the 
gemcitabine-paclitaxel population was LE0.62, LE2.60 and LE5.77 for year 1, 2 and 
3 respectively while for the capecitabine-docetaxel population was LE0.59, LE2.54 
and LE5.70 for year 1, 2 and 3 respectively. The capecitabine-docetaxel results 
were most sensitive to the cost of everolimus while gemcitabine-paclitaxel results 
were most sensitive to the number of eligible patients. ConClusions: Increased 
acquisition costs of everolimus-exemestane for HR+, HER2-MBC treatment 
are expected to be obviously offset by both the reduced number of progressed patients 
and the relatively small medical costs due to avoided adverse events of each of gem-
citabine-paclitaxel and capecitabine-docetaxel regimens. The expected budget impact 
of covering everolimus for this group of patients was relatively small.
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bACkgRound: Chronic Lymphocytic Leukemia (CLL) is a malignant disease incur-
able of the lymphoid system, that affects predominantly elderly, especially in 
Western countries. Your treatment when necessary is based on the administration 
of chemotherapy, with association of fludarabine plus cyclophosphamide (FC), the 
most widely used schema. Recently the addition of rituximabe, a monoclonal anti-
body has been associated with this scheme, known as FCR. objeCtives: To elabo-
rate a budget impact analysis (BIA) of rituximab for chronic lymphocytic leukemic 
for help the decision making. Methods: A BIA of association of fludarabine plus 
cyclophosphamide in SUS compared to rituximab with this scheme was performed. 
The analysis’ time horizon was 5 years, using a CLL prevalence of 4.4% and 25% of 
CLL refractory between them (1.634), considering an annual growth rate of 0.8143% 
and a market share of 25% and 75% according the classification of diagnosis and 
stage of Rai & Keating. The mean total rituximab dose considered was 375/mg/
m2, with an average personal weight and size of 70kg and 1,70m, which means 
681,75mg per cicle. All cost purchase prices and remission rate of rituximab (22%) 
and stand chemiterapy (9%) were obtained at one year trial in the onco-hematol-
ogy high complexity Clinical Hospital of the Faculty of Medicine of Ribeirão Preto 
HCFMRP / USP hospital measured in real 2012. Results: The budget impact of FC 
per year would be 38.7m reais ($17.5m) in the 1st year, considering 25% of target 
population, reaching approximately 135.3m reais ($60.9m) in 75% of patients. For 
RFC, the budget impact would be 97 million reais ($43.6m) in the 1st year, reaching 
340 million reais ($153m) in 75% of patients. ConClusions: Treatment costs still 
impressive, considering that rituximab ’ values reach 2.5 times the clicle unit values 
of standart chemioperapy, fact that did not happen in other countries where they 
are already covered.
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by targeting prophylaxis based on patient genotype. The deterministic sensitivity 
analysis showed that the savings is most dependent on the incidence of invasive 
fungal infection, cost of treating an invasive fungal infection, and frequency of *17 
in the population. ConClusions: Genotyping AML patients for CYP2C19*17 prior to 
induction-consolidation is expected to be cost-neutral or potentially cost-saving by 
reducing the incidence of invasive fungal infections compared to standard prophy-
laxis. These results may mitigate potential budgetary concerns, thereby reducing 
barriers to a test that can be clinically beneficial to AML patients.
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objeCtives: In the latest years several drugs demonstrated to increase survival 
in mCRPC patients post chemotherapy failure. However, issues remain related to 
the treatment sequencing of these drugs. The aim of this study is to estimate the 
budget impact of the introduction of enzalutamide in the Brazilian Private Health 
System. Methods: A deterministic state transition budget impact model (BIM) 
was developed to estimate treatment costs of mCRPC patients after chemotherapy 
failure over a 3-year time horizon. Budget impact was estimated comparing a base-
line scenario including mandatory coverage drugs (abiraterone, cabazitaxel) with 
an alternative scenario including all treatment options (abiraterone, cabazitaxel 
and enzalutamide). Target population, dosing, duration of therapy and sequenc-
ing was based on scientific literature. Pharmaceutical direct costs were based on 
factory price, assuming parity price of enzalutamide and abiraterone. Univariate 
Deterministic sensitivity analysis was conducted to determine the impact of param-
eters on results. Results: The BIM estimates that a total of 5,789 patients will be 
treated in the next three years, with annual cost estimates in the baseline scenario 
of R$83,944,041 in year 1, reaching R$198,507,065 in year 3 of the simulation. The 
introduction of enzalutamide would incur a total increase in costs of R$16,649,325 
after 3 years. In deterministic sensitivity analysis, enzalutamide price, proportion of 
patients receiving additional treatment line and duration of therapy were the most 
important variables that impacted results, with the alternative scenario remaining 
more costly than the baseline scenario in all simulations, incurring additional costs 
ranging from R$6,634,955 to R$38,818,233. ConClusions: Considering current 
available evidence regarding treatment sequencing, the introduction of enzaluta-
mide is expected to increase costs to the Brazilian Private Health System.
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objeCtives: To assess the economic impact of Ceplene® with low-dose Interleukin-2 (IL-2) 
for the treatment of adult patients with Acute Myeloid Leukemia (AML) in first complete 
remission (CR-1) which previously received intensive chemotherapy in Spain. Methods: 
A budget impact model was developed using the perspective of the Spanish 
National Health System with a 4-year time horizon. Ceplene®/IL-2 was compared 
with no treatment and an unrelated allogenic hematopoietic stem cell transplant 
(allo-HSCT). For both treatment options and no treatment, health care costs (EUR 
2013) including medical visits, hospitalisations, laboratory and diagnostic tests, 
prophylactic measures, treatment of complications and infections were consid-
ered. Average treatment costs per patient up to a maximum of three years were 
estimated for both treatment options and no treatment depending on the prob-
ability of overall survival without or with a relapse, and death without relapse, as 
well as the duration until relapse or death without relapse during this period. Total 
annual health care costs were estimated based on the annual per patient cost, the 
target population, and the market shares associated with each option, before and 
after the introduction of Ceplene®/IL-2. Results: Patients eligible for Ceplene®/
IL-2 were estimated at 1,502 in 2013 with a small increase up to 1,509 in 2016. 
The overall budget impact with the introduction of Ceplene®/IL-2, is estimated to 
decrease with € 674,149 and € 728,945 in 2014 and 2016, and an increase of € 202,322 
in 2015. Overall budget impact savings over the period 2014-2016 are estimated at 
€ 1,130,894. ConClusions: The introduction of Ceplene®/IL-2 as maintenance therapy 
supposes savings in the budget impact for the treatment of AML patients in CR-1 in Spain. 
Ceplene®/IL-2 is expected to fulfil a direct medical need for patients not eligible or having 
an unfavourable profile for an unrelated allo-HSCT receiving no treatment, and those who 
received an unrelated allo-HSCT with unfavourable prognostics.
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objeCtives: Standard treatment for lung cancer (LC) in Mexico is chemotherapy. 
Crizotinib is the only therapy approved for patients with ALK+ advanced non-small 
cell lung cancer (NSCLC), a low prevalence condition. This analysis aims to estimate 
the economic impact of using crizotinib for patients with ALK+ advanced NSCLC 
in the Mexican setting from public health care institution perspective. Methods: 
A budget impact analysis with a one-year time horizon was developed to compare 
expected costs that the Mexican Social Security Institute (IMSS) and the Safety and 
Social Services for State Workers Institute (ISSSTE) public health care institutions 
would incur if they were to include crizotinib on their formularies. Using epidemiol-
ogy data from published sources, a total of 3,023 potential patients with LC were 
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recombinant human granulocyte colony stimulating factor (pegfilgrastim) to reduce 
the risk of FN, the incidence rate of FN was 39.5% in the control group, while it 
was 3.04% in the pegfilgrastim group. Pegteograstim (Neulageg®) was shown to 
be non-inferior compared to pegfilgrastimin the phase three clinical trial, so the 
result was directly applied. The number of patients to whom the result applies was 
estimated as 1,440 patients, which is 8% of the annual average number of breast 
cancer patients in South Korea. The hospitalization costs for FN was estimated by 
an average costs of 18 patients admitted to a Catholic University hospital in 2013, 
which was 15,396,014 (±18,847,475) KRW. Costs for isolated ward, 3rd generation 
antibiotics and G-CSF were included on the hospitalization costs for FN. Weighted 
average costs given by Health Insurance Review & Assessment Service were used for 
micro-costing. Results: When assuming an average incidence rate of 20% for FN, 
FN will occur in 1.72% (25 patients), which is a 8.6% decrease with pegfilgrastim as 
well as with pegteograstim. Therefore, when estimating at the sum of the costs of 
pegfilgrastim, pegteograstim and the average cost of hospitalization, the total cost is 
5,572,986,587 KRW for pegfilgrastim while it is 3,499,386,587 KRW for pegteograstim. 
On the other hand, when pegfilgrastim or pegteograstim are not used, the incidence 
rate of FN is 20% (288 patients), and the average cost of hospitalization after FN 
occurs is 4,434,052,032 KRW. ConClusions: When pegteograstim is reimbursed to 
reduce the incidence of FN during chemotherapies for breast cancer with moderate 
risk of FN, about 1 billion KRW saving is expected from a payer perspective.
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objeCtives: Cancer patients are susceptible to infections, including pneumo-
nia, due to immunosuppressive therapies associated with cancer treatment. This 
study aimed to evaluate the budget impact of pneumonia in patients with previ-
ous diagnosed cancer in the Brazilian Private Health System. Methods: Orizon 
database (N= 18 million lives) was used to identify patients with any type of cancer 
followed by a pneumonia hospitalization between October 2010 and December 2013. 
Pneumonia was identified using code of A40.3, B95.3, G00.1, J13, J15, J15.0, J15.3, J15.4, 
J15.8, J15.9, J18, J18.0, J18.9, J20.2, P23.3. Inpatient and related outpatient costs were 
included. Results: A total of 68,717 patients with a pneumonia hospitalization 
were identified. Of those, 2,769 were diagnosed with cancer (WCa) before the pneu-
monia hospitalization for a total of 3,605 hospitalizations. This translated to a mean 
of 1.30 hospitalization per WCa patient. The group without cancer diagnosis (WoCa), 
65,948 pneumonia patients had a total of 81,583 hospitalizations for a mean of 1.24 
hospitalizations. The average costs per patient are BRL2,863.08 for the WoCa group 
and BRL9,288.07 for the WCa group. When considered the costs per hospitalizations 
the values are BRL2,314.60 and BRL7,134.16 respectively. ConClusions: Although 
the number of pneumonia hospitalization per patient was slightly higher in WCa 
compared with WoCA patients, the cost per patient and cost per hospitalization 
was at least 3 times higher in the WCa compared with WoCA patients. This suggests 
pneumonia has a substantial financial impact in patients with cancer who are in 
the Brazilian Private Health System.
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objeCtives: Several multigene prognostic and predictive tests have recently been 
launched. The 21-gene assay (OncotypeDX®), a validated gene expression profil-
ing test that predicts the likelihood of adjuvant chemotherapy benefit in patients 
with early stage breast cancer, was found to be cost-effective and recommended 
in several guidelines. Its use in clinical practice in France is limited because of 
the absence of reimbursement. This study aims to determine if the utilisation of 
the 21-gene assay in private hospitals would provide good value for money from 
a collective perspective in France and whether hospitals can afford using the test 
under the current payment system. Methods: A multicenter retrospective study 
was conducted to estimate the cost of adjuvant chemotherapy from societal and 
national insurance perspectives. The resulting estimate was used as an input of 
a Markov model to assess the cost-effectiveness of the 21-gene assay from the 
French collective perspective and the economic impact of the test on the revenue 
in private hospital organizations. Results: The cost of adjuvant chemotherapy in 
private hospitals was estimated at € 8,218 per patient from the national insurance 
perspective (€ 10,305 from the societal perspective). The 21-gene assay was found 
cost-effective compared to standard practice and cost-saving with inclusion of pro-
ductivity costs. The absence of reimbursement involves a deficit for private hospitals 
of € 3,200 per patient tested. ConClusions: Providing the 21-gene assay in French 
private hospitals would be cost-effective in the French collective perspective. In the 
absence of reimbursement from primary payers, some private hospitals may cover 
the costs of companion diagnostics to improve their attractiveness, but the test 
will be underused, thus depriving patients from a technology that could improve 
their quality of life and using resources that could be freed up for other patients.
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objeCtives: To analyze cost-effectiveness and assses budget impact of novel BRAF 
inhibitors – vemurafenib and dabrafenib – in patients with MMM. Methods: In the 
absence of head to head data we derived a decision model from indirect comparison 
objeCtives: Cancer patients undergo a wide range of laboratory procedures, from 
simple blood tests to complex molecular diagnostics. In cost-effectiveness analyses, 
costs of laboratory testing are often ignored or estimated inappropriately. We present 
real-world costs of laboratory procedures for non-small cell lung cancer (NSCLC) 
patients, per category of laboratory testing. Methods: In a Dutch academic hospi-
tal, all laboratory tests performed for NSCLC patients between 2009 and 2011, were 
recorded and categorized in clinical chemistry; pathology; microbiology; serology, 
hematology, transfusion; pharmacology; and other or unknown. Number of tests per 
type were multiplied with unit costs per test obtained from The Dutch Healthcare 
Authority. Results: 1,015 patients were included, with a total of 171,632 laboratory 
procedures. 392 different types of tests were performed. Mean cost for laboratory 
testing is EUR1,175 (95%CI 1,066-1,283) per patient. For cost allocation and modeling 
purposes, cost per month with laboratory testing (EUR265,95%CI 247-282) and cost 
per day with laboratory testing (EUR96, 95%CI 91-100) are presented. Costs are mainly 
driven by (molecular) pathology (26%), other (25%, mainly order processing fees) and 
clinical chemistry (24%, due to high test volumes). ConClusions: Costs of laboratory 
procedures for NSCLC patients are substantial. Relatively simple blood tests contrib-
ute significantly to these costs due to high test volumes. Main cost driver however 
is molecular testing by the pathologist, for the use of targeted therapies. In pharma-
coeconomic evaluations, taking laboratory costs into account significantly impacts 
results, especially when testing practices differ between treatment alternatives.
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objeCtives: To estimate the budgetary impact of the introduction of PET-CT for 
staging non-small-cell lung carcinoma (NSCLC) in Brazilian Public Healthcare 
System (SUS). Methods: For estimation of the budgetary impact the work con-
sidered patients diagnosed with NSCLC that would be submitted to the PET-CT for 
tumor staging. It was considered the time horizon of 2013, 2014 and 2015. The num-
ber of procedures in those years was calculated from an estimate of the years 2008-
2012, obtained from SUS. It was assumed that by 2013 the demand for PET grows due 
to its incorporation and, from then on, there would be a tendency to annual decrease 
of 7.5%, the same as in previous years. Cost estimates were obtained from recent 
cost-effectiveness literature. Results: The average cost of the PET-CT procedure 
calculated in 2012 is $1,229.92, the value used for 2013 approximately. The 2014 and 
2015 values were adjusted for inflation at rate of 5% per year, resulting $1,291.40 
and $1,355.97, respectively. The total budget impact for each year was calculated 
by multiplying the number of procedures to be performed by its base value minus 
the savings achieved. The values of $2,072,300.84, $2,030,645.11 and $1,988,842.77, 
for the years 2013, 2014 and 2015, were found respectively. ConClusions: The 
introduction of PET-CT in the staging of NSCLC affects the budget of the Ministry 
of Health in 21.8%, 19.6% and 17.5% in the years 2013, 2014 and 2015, respectively.
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objeCtives: The objective of this study was to estimate the incremental Budget 
Impact (BI) and survival benefit of utilizing eribulin for treatment of Metastatic 
Breast Cancer (MBC) in patients with 2-5 prior chemotherapy regimens includ-
ing anthracycline and taxane. Methods: Epidemiology was derived from 2013 
CancerMPact report and National databases (FOSP and INCA). Treatment of 
Physician’s Choice (TPC) arm included capecitabine, gemcitabine, vinorelbine, 
docetaxel and paclitaxel. TPC market shares, efficacy and Adverse Events (AE) data 
were taken from Phase III clinical trial. Total costs comprised of drug costs, admin-
istration costs, direct medical and AE costs. A micro-costing analysis of resource 
utilization for AE treatments and disease management pre and post progressions 
was performed. Local Brazil tariffs for each costs unit were applied to an Excel-based 
model to compare total costs and survival rates with and without eribulin for MBC 
patients across a 5-year horizon from private payers perspective (assumed to cover 
25% of Brazil population). Results: Applying an MBC prevalence rate, proportion 
of patients with active disease and treated with 3rdline chemotherapies the model 
estimates up to 801 patients treated with eribulin out of 3864 eligible patients over 
5 years. Assuming eribulin market share of 2%, 5%, 9%, 14% and 20% in years 1, 2, 3, 
4 and 5, the BI is R$294K, R$741K, R$1345K, R$2111K and R$3043K (net increase of 
0.12% - 1.21%). The main cost offsets include the displacement of more widely-used 
TPC therapies. Eribulin MBC treatment in Brazil is estimated to yield an incremental 
245 progression free patient years and 408 life years in population covered by private 
insurance. ConClusions: Given the limited number of effective treatment options 
available to patients receiving third line chemotherapy, eribulin represents a much 
needed therapy option for this population. With additional survival benefits eribulin 
represents an effective innovative approach to MBC management.
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objeCtives: To conduct a budget impact analysis on the use of Pegteograstim 
(Neulageg®) to reduce the risk of febrile neutropenia (FN) during chemotherapies 
for breast cancer with moderate risk compared to a standard treatment with anti-
biotics and G-CSF after occurrence of FN. Methods: The efficacy of pegylated 
